New York’s attorney general investigates EpiPen manufacturer
ALBANY, N.Y. — The state attorney general’s office is investigating whether Mylan Pharmaceuticals unfairly limited competition for its emergency allergy treatment EpiPen, which has been criticized for steep price increases.
A preliminary review showed the company “may have inserted potentially anticompetitive terms” into sales contracts with many school systems, Democratic Attorney General Eric Schneiderman said Tuesday.
“If Mylan engaged in anti-competitive business practices, or violated antitrust laws with the intent and effect of limiting lower cost competition, we will hold them accountable,” Schneiderman said. “Allergy sufferers have enough concerns to worry about. The availability of life-saving medical treatment should not be one of them.”
Subpoenas for company information were issued last week.